BioSyntech is analysing the clinical data from 41 patients at 12 month follow-up in the ongoing Canadian/European clinical trial assessing the efficacy and safety BST-CarGel versus microfracture. Final clinical results of this pivotal study are anticipated in the summer of 2010.